Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1792907 | 0.90 | CYP1A2 (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL1795787 | 0.86 | SMN1; SMN2 (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL1795347 | 0.86 | CYP1A2 (0.48) | TP53NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL1793853 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL1798156 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL1797133 | 0.82 | GRM4 (0.49) | HSD17B10TSHRTP53NPC1RAB9A | |
| SCHEMBL1795478 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL30761123 | 0.79 | CYP1A2 (0.69) | CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL1798177 | 0.77 | GRM5 (0.53) | HSD17B10 | |
| SCHEMBL1796965 | 0.77 | CYP3A4 (0.70) | TSHRTP53NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951824-B2 | 4-aryl-pyridine-2-carboxyamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | claimed |
| EP-1987003-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| US-7951824-B2 | 4-aryl-pyridine-2-carboxyamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1987003-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093542-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197553-A1 | 4-Aryl-pyridine-2-carboxyamide derivatives | GRM2, GRM1, GRM3 | HSD17B10 3520/4885TDP1 4492/4885CYP11B2 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.